Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis

Completed · Phase 4

Conditions studied: Allergic Rhinitis

In brief

To compare patient perceptions of the sensory attributes, including taste and aftertaste, of Olopatadine relative to azelastine when administered as a single dose in patients with allergic rhinitis.

Key facts

Study ID

NCT00772304

Run by

Alcon Research

People needed

102

Starts

2008-10-01

Last updated by the study team

2010-03-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Must have a history (at least 2 yrs) of allergic rhinitis and be symptomatic at time of enrollment
• 18 yrs of age or older
• Read and sign informed consent
• Females of childbearing potential may participate if: are non-breast feeding, have negative urine pregnancy test at visit 1, agree to take urine pregnancy test upon exiting study, do not intend to become pregnant during the study, are using adequate methods of birth control.

You may not qualify if…

• History of intolerance or hypersensitivity to any component of the study medications, including benzalkonium chloride.
• Any disease or systemic disorder that may complicate or interfere with investigation or evaluation of the study medications (including but not limited to): Rhinitis medicamentosa, large obstructive nasal polyps, history (w/in last 3 months) of nasal septic ulcers, nasal surgery or nasal trauma, history or evidence of nasolacrimal drainage system malfunction, history (w/in 30 days) or evidence of sinusitis or upper or lower respiratory infection.
• Impairment of sense of tast or smell (self reported)
• Asthma, except for mild, intermittent asthma (nat'l Asthma guidelines)
• Congestion, that in the opinion of the investigator, that would interfere with successful nasal drug administration/absorption
• Patients w/a severe impairment of nasal breathing
• Anatomic abnormalities of as identified by nasal examination
• History of or current severe or uncontrolled cardiovascular, hepatic, renal and/or other disease/illness that could interfere w/study.
• History of (w/in past 12 months) or ongoing clinically relevant electrolyte abnormalities.

Where it is running

• Alcon Call Center for Trial Locations — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.